Lamivudin/Zidovudin

Lamivudine and Zidovudine, the active ingredients in Lamivudin/Zidovudin, are nucleoside reverse transcriptase inhibitors presented as a tablet for oral use. They are prescribed to manage HIV-1 infection by inhibiting viral replication in adults and children.

GNH USA supplies Lamivudin/Zidovudin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lamivudin/Zidovudin is a nucleoside reverse transcriptase inhibitor used in antiretroviral regimens for HIV infection.

- HIV‑1 infection: suppresses viral replication and helps restore CD4+ cell counts. - AIDS‑related opportunistic infections (as part of HAART): reduces the risk of disease progression. - Prevention of mother‑to‑child transmission (combined therapy): lowers viral load in pregnant women to protect the newborn.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Headache: transient cranial discomfort. - Fatigue: generalised tiredness. - Anemia: reduced red blood cell count. - Diarrhoea: loose stools. - Neutropenia: lowered neutrophil count.

Serious or Rare Side Effects: - Lactic acidosis: accumulation of lactate with metabolic disturbance. - Severe neutropenia: markedly low neutrophil levels increasing infection risk. - Hepatic steatosis: fatty change in the liver. - Hypersensitivity reactions: rash, fever, or organ involvement. - Pancreatitis: inflammation of the pancreas. - Bone‑marrow suppression: pancytopenia affecting multiple blood cell lines.

Patients should be monitored for safety and efficacy throughout therapy.

- Renal function: assess creatinine clearance in severe impairment. - Hepatic function: monitor liver enzymes regularly. - Hematologic parameters: check complete blood count for anemia or neutropenia. - Pregnancy: use only when benefits outweigh potential risks. - Drug resistance: avoid monotherapy to prevent viral resistance. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Lamivudin/Zidovudin may interact with several concomitant medications.

Major Interactions (Avoid): - Didanosine: increased risk of pancreatitis. - Stavudine: heightened mitochondrial toxicity. - Alcohol: may exacerbate hepatic injury.

Moderate Interactions (Monitor Closely): - Nephrotoxic drugs: monitor renal function closely. - Anticoagulants (e.g., warfarin): may affect INR values. - Protease inhibitors: can raise plasma concentrations of zidovudine.